SUNSET, La., July 29, 2015 (GLOBE NEWSWIRE) -- A new study shows patients with Major Depressive Disorder and the MTHFR enzyme polymorphism significantly benefit from reduced B vitamin therapy, marketed under the prescription trade name, EnLyte. 60% of the US population, and up to 90% of those struggling with depression, have the MTHFR enzyme polymorphism, which hinders the metabolism of critical B vitamins and cofactors.
MTHFR polymorphism leads to impaired folate metabolism and is directly correlated with elevated homocysteine (hyperhomocysteinemia). Homocysteine is a toxic amino acid linked to major depressive disorder, treatment resistant depression and treatment failures, bipolar disorder, anxiety, schizophrenia, dementia and cognitive decline, Parkinson's, brain atrophy, and many other serious health conditions.
The study "Reduced B Vitamin Therapy in MTHFR C677T/A1298C Patients with Major Depressive Disorder-Clinical Response Correlates with Homocysteine Reduction: A Double-Blind, Placebo-Controlled Study" was conducted by Arnie Mech, MD, Mech Healthcare Associates, with collaboration by Andrew Farah, MD, Chief of Psychiatry, High Point Division of UNC Healthcare.
330 confirmed polymorphic patients with Major Depressive Disorder were randomized to receive either placebo or EnLyte Gelcaps as monotherapy once daily for 8 weeks.
Homocysteine levels were drawn at baseline and 8 weeks; MADRAS scores were administered to determine depression remission rates to each agent.
The EnLyte group showed a separation from placebo by week 2 of both depression scores and homocysteine levels. At week 8, 42% of the EnLyte group had achieved remission of depression. Homocysteine levels were reduced 33% by week 8 in the EnLyte group. In the placebo group, homocysteine levels continued to increase over the course of the study. The EnLyte group reported a side effect profile comparable to placebo.
"These results confirm the homocysteine theory of depression and the therapeutic benefit and safety of using reduced B vitamins (EnLyte) as monotherapy in depressive disorders particularly in the presence of MTHFR polymorphisms." Andrew Farah, MD
EnLyte is an advanced generation folate therapy by prescription FDA regulated to treat conditions related to hyperhomocysteinemia and/or suboptimal folate levels including as monotherapy or adjunctive therapy to an SSRI/SNRI in depression. EnLyte contains L-methylfolate magnesium, folinic acid, folacin, brain-ready cofactors of b1, b2, b3, b6, b12, betaine, zinc, magnesium, vitamin c, and PS gold omega 3s. EnLyte is pregnancy category A and safe for use in children. EnLyte is paid by many insurance plans at a reasonable copay and available through cash pay mail order for $58 per month. For more information or licensed prescriber samples, contact EnLyte Customer Care, 985.788.7755 or visit www.EnLyteRx.Com.
CONTACT: Angela Hall 850-602-1617 firstname.lastname@example.orgSource:JayMac Pharmaceuticals